Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.

@article{OSullivan2007ImatinibPO,
  title={Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.},
  author={Susannah O'Sullivan and Dorit Naot and Karen E. Callon and Fran Porteous and Anne Horne and Diana J Wattie and Maureen Watson and J. Cornish and Peter J Browett and Andrew Grey},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2007},
  volume={22 11},
  pages={1679-89}
}
UNLABELLED Several lines of evidence suggest that imatinib may affect skeletal tissue. We show that inhibition by imatinib of PDGFR signaling in osteoblasts activates osteoblast differentiation and inhibits osteoblast proliferation and that imatinib inhibits osteoclastogenesis by both stromal cell-dependent and direct effects on osteoclast precursors. INTRODUCTION Imatinib mesylate, an orally active inhibitor of the c-abl, c-kit, and platelet-derived growth factor receptor (PDGFR) tyrosine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…